The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.
 
Michael Paul Kolinsky
Travel, Accommodations, Expenses - Novartis
 
Pasquale Rescigno
No Relationships to Disclose
 
Diletta Bianchini
Speakers' Bureau - Janssen
Travel, Accommodations, Expenses - Janssen
 
Zafeiris Zafeiriou
No Relationships to Disclose
 
Niven Mehra
No Relationships to Disclose
 
Joaquin Mateo
Travel, Accommodations, Expenses - AstraZeneca; Sanofi
 
Ruth Riisnaes
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Mateus Crespo
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Ines Figueiredo
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Penelope Flohr
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Nina Tunariu
No Relationships to Disclose
 
Udai Banerji
Consulting or Advisory Role - Astex Pharmaceuticals; Novartis
Research Funding - AstraZeneca; Chugai Pharma; Onyx
 
Florence I. Raynaud
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Karen E Swales
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Holly Tovey
Research Funding - AstraZeneca (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Nuria Porta
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Rachel Slade
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Lorna Leonard
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Emma Hall
Research Funding - Accuray (Inst); AstraZeneca (Inst); Aventis Pharma (Inst); Bayer (Inst)
Patents, Royalties, Other Intellectual Property - Rewards to Inventors Scheme (Inst)
Other Relationship - ICR has commercial interest in AZD5363
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex